Slate Medicines launched with $130 million in Series A financing to advance anti-PACAP antibodies for the prevention of migraine and other headache disorders, co-led by RA Capital Management and Forbion with participation from Foresite Capital and an undisclosed biotech investor. The Raleigh, North Carolina-based company’s lead program, SLTE-1009, is a monoclonal antibody licensed from Guangdong-based DartsBio Pharmaceuticals, and is on track to enter Phase 1 trials in mid-2026.

The financing arrives as migraine prevention has already been transformed once by the CGRP class, a group of monoclonal antibodies and small molecules that gave patients meaningful relief after decades of repurposed treatments borrowed from epilepsy, depression and hypertension. Yet a substantial share of migraine patients do not respond adequately to CGRP-targeted therapies, leaving room for a mechanistically distinct approach. PACAP, or pituitary adenylate cyclase-activating polypeptide, is a neuropeptide involved in pain signaling, stress response and vascular regulation that has been independently validated as a migraine trigger in human provocation studies, where infusion of PACAP reliably induces migraine-like attacks in susceptible individuals.

SLTE-1009 is designed with half-life extension technology intended to allow infrequent subcutaneous dosing, a format investors and patients have come to expect following the CGRP class’s success with similarly convenient administration. By licensing a clinical-stage asset from DartsBio rather than starting from a discovery-stage program, Slate is aiming to compress the timeline to human proof-of-concept data relative to a company building an anti-PACAP franchise from scratch.

The deal also reflects a broader pattern in 2026 biotech financing, in which venture investors have shown a preference for de-risked, licensed-in assets over purely internal discovery bets, particularly in neurology and psychiatry, where trial costs and placebo response rates make early clinical validation especially valuable. Forbion and RA Capital have both been active investors in headache and broader CNS drug development, and the involvement of two specialist life sciences funds alongside a Series A round of this size signals continued institutional appetite for differentiated neurology assets even as overall biotech fundraising remains selective.

If early trials confirm PACAP blockade translates into migraine prevention with a tolerability profile competitive with existing CGRP therapies, Slate would be positioned to address patients who cycle through multiple preventive regimens without adequate relief, a population that remains sizable despite the CGRP class’s success. The company’s approach also underscores how migraine, once a therapeutic area starved of dedicated investment, has become one of neurology’s more active arenas for new mechanism validation, drawing venture capital toward a broader set of neuropeptide and ion channel targets beyond CGRP alone.

Slate’s near-term milestones will center on safety and pharmacokinetic data from the Phase 1 program, with investors and prospective partners watching closely for early signals on dosing interval and injection site tolerability before committing to the larger studies needed to establish efficacy in a chronic migraine population.